Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| QuidelOrtho CorpQDEL · Entity 4986 | EVP & CCO | June 01, 2024 | June 04, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
QuidelOrtho Corp
Report date June 01, 2024 · Filed June 04, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 16,644 |
Ending reported balance
After 2024-06-01 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2024-06-01 · Grant · Acquired 3,594 · Balance 17,944 F1: Reflects release of restricted stock units that were previously reported on a Form 4. Row 2 · 2024-06-01 · Tax withholding · Disposed 1,300 · Balance 16,644 F2: Disposition of shares, as set forth above, was in connection with the Issuer's withholding of common shares to satisfy tax withholding obligations related to the issuance of common shares upon release of restricted stock units. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 3,594 |
Reported balance
After 2024-06-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-06-01 · Exercise / conversion · Disposed 3,594 · Balance 3,594 F3: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F4: 3,594 shares vested on June 1, 2024; the remaining 3,594 shares will vest on June 1, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects release of restricted stock units that were previously reported on a Form 4.
F2: Disposition of shares, as set forth above, was in connection with the Issuer's withholding of common shares to satisfy tax withholding obligations related to the issuance of common shares upon release of restricted stock units.
F3: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock.
F4: 3,594 shares vested on June 1, 2024; the remaining 3,594 shares will vest on June 1, 2025.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Ortho Clinical Diagnostics Holdings plc
Report date May 27, 2022 · Filed June 01, 2022
Section 16 reporting ended · disclosed 2022-06-01. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary Shares, $0.00001 par valueSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2022-05-27 transaction · row 1
1 source rowRow 1 · 2022-05-27 · Disposition to issuer · Disposed 150,000 · Balance 0 F1: Reflects restricted stock units. F2: Pursuant to the Business Combination Agreement, dated December 22, 2021 (the "BCA"), by and among Coronado Topco, Inc. ("Coronado Topco"), Laguna Merger Sub, Inc., Orca Holdco, Inc., Orca Holdco 2, Inc., Quidel Corporation and the Issuer, the Issuer became a wholly owned subsidiary of Coronado Topco upon consummation of the business combinations (the "Effective Time"). At the Effective Time: (a) each of the Issuer's ordinary shares was automatically converted into the right to receive (i) 0.1055 shares of common stock of Coronado Topco and (ii) $7.14 in cash; and (b) each restricted stock unit, whether vested or unvested, was converted into a Coronado Topco equity right of the same type and on the same terms and conditions as were applicable to the corresponding restricted stock unit immediately prior to the Effective Time, which right shall be settled in cash upon vesting. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $6.28 · Expires 2025-12-21 | Direct | 0 |
Reported balance
After 2022-05-27 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-05-27 · Disposition to issuer · Disposed 208,735 · Balance 0 F3: At the Effective Time, each stock option, whether vested or unvested, was converted into (a) a Coronado Topco stock option on the same terms and conditions as were applicable to such stock option immediately prior to the Effective Time, except as adjusted by the BCA, (b) with respect to the portion of such stock option that is vested as of the Effective Time, the right to receive payment, in cash, equal to the cash consideration payable in respect of the Issuer's securities subject to the vested portion of such stock option and (c) with respect to the portion of such stock option that is not vested as of the Effective Time, the right to receive payment, in cash, equal to the cash consideration payable in respect of the Issuer's securities subject to the unvested portion of such stock option when it vests in accordance with its terms. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $12.56 · Expires 2029-12-20 | Direct | 0 |
Reported balance
After 2022-05-27 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-05-27 · Disposition to issuer · Disposed 239,010 · Balance 0 F3: At the Effective Time, each stock option, whether vested or unvested, was converted into (a) a Coronado Topco stock option on the same terms and conditions as were applicable to such stock option immediately prior to the Effective Time, except as adjusted by the BCA, (b) with respect to the portion of such stock option that is vested as of the Effective Time, the right to receive payment, in cash, equal to the cash consideration payable in respect of the Issuer's securities subject to the vested portion of such stock option and (c) with respect to the portion of such stock option that is not vested as of the Effective Time, the right to receive payment, in cash, equal to the cash consideration payable in respect of the Issuer's securities subject to the unvested portion of such stock option when it vests in accordance with its terms. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $12.56 · Expires 2030-07-27 | Direct | 0 |
Reported balance
After 2022-05-27 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2022-05-27 · Disposition to issuer · Disposed 79,670 · Balance 0 F3: At the Effective Time, each stock option, whether vested or unvested, was converted into (a) a Coronado Topco stock option on the same terms and conditions as were applicable to such stock option immediately prior to the Effective Time, except as adjusted by the BCA, (b) with respect to the portion of such stock option that is vested as of the Effective Time, the right to receive payment, in cash, equal to the cash consideration payable in respect of the Issuer's securities subject to the vested portion of such stock option and (c) with respect to the portion of such stock option that is not vested as of the Effective Time, the right to receive payment, in cash, equal to the cash consideration payable in respect of the Issuer's securities subject to the unvested portion of such stock option when it vests in accordance with its terms. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects restricted stock units.
F2: Pursuant to the Business Combination Agreement, dated December 22, 2021 (the "BCA"), by and among Coronado Topco, Inc. ("Coronado Topco"), Laguna Merger Sub, Inc., Orca Holdco, Inc., Orca Holdco 2, Inc., Quidel Corporation and the Issuer, the Issuer became a wholly owned subsidiary of Coronado Topco upon consummation of the business combinations (the "Effective Time"). At the Effective Time: (a) each of the Issuer's ordinary shares was automatically converted into the right to receive (i) 0.1055 shares of common stock of Coronado Topco and (ii) $7.14 in cash; and (b) each restricted stock unit, whether vested or unvested, was converted into a Coronado Topco equity right of the same type and on the same terms and conditions as were applicable to the corresponding restricted stock unit immediately prior to the Effective Time, which right shall be settled in cash upon vesting.
F3: At the Effective Time, each stock option, whether vested or unvested, was converted into (a) a Coronado Topco stock option on the same terms and conditions as were applicable to such stock option immediately prior to the Effective Time, except as adjusted by the BCA, (b) with respect to the portion of such stock option that is vested as of the Effective Time, the right to receive payment, in cash, equal to the cash consideration payable in respect of the Issuer's securities subject to the vested portion of such stock option and (c) with respect to the portion of such stock option that is not vested as of the Effective Time, the right to receive payment, in cash, equal to the cash consideration payable in respect of the Issuer's securities subject to the unvested portion of such stock option when it vests in accordance with its terms.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 01, 2024 Filed Jun 4, 2024 16:15 UTC | QuidelOrtho Corp QDEL · Entity 4986 | Exercise / conversionRestricted Stock Units · Derivative | 3,594 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-068686 · ownership.xml · derivative · entry 3 Iskra Michael S. · CIK 0001839432 · EVP & CCO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,594 Underlying: Common Stock · 3,594 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F4 · derivative.exercise_date: 3,594 shares vested on June 1, 2024; the remaining 3,594 shares will vest on June 1, 2025. F4 · derivative.expiration_date: 3,594 shares vested on June 1, 2024; the remaining 3,594 shares will vest on June 1, 2025. Read SEC document |
| June 01, 2024 Filed Jun 4, 2024 16:15 UTC | QuidelOrtho Corp QDEL · Entity 4986 | Tax withholdingCommon Stock | 1,300 | $44.19 | $57,447.00 |
DisclosureSEC source: 0000950170-24-068686 · ownership.xml · nonDerivative · entry 2 Iskra Michael S. · CIK 0001839432 · EVP & CCO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,644 F2 · shares: Disposition of shares, as set forth above, was in connection with the Issuer's withholding of common shares to satisfy tax withholding obligations related to the issuance of common shares upon release of restricted stock units. Read SEC document |
| June 01, 2024 Filed Jun 4, 2024 16:15 UTC | QuidelOrtho Corp QDEL · Entity 4986 | GrantCommon Stock | 3,594 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-068686 · ownership.xml · nonDerivative · entry 1 Iskra Michael S. · CIK 0001839432 · EVP & CCO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,944 F1 · shares: Reflects release of restricted stock units that were previously reported on a Form 4. Read SEC document |
| March 28, 2024 Filed Apr 1, 2024 20:00 UTC | QuidelOrtho Corp QDEL · Entity 4986 | Exercise / conversionRestricted Stock Units · Derivative | 4,925 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-039668 · ownership.xml · derivative · entry 3 Iskra Michael S. · CIK 0001839432 · Interim CEO, EVP & CCO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,850 Underlying: Common Stock · 4,925 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F5 · derivative.exercise_date: 4,925 shares vested on March 28, 2024; the remaining 9,850 shares will vest in equal installments on March 28, 2025 and March 28, 2026. F5 · derivative.expiration_date: 4,925 shares vested on March 28, 2024; the remaining 9,850 shares will vest in equal installments on March 28, 2025 and March 28, 2026. Read SEC document |
| March 28, 2024 Filed Apr 1, 2024 20:00 UTC | QuidelOrtho Corp QDEL · Entity 4986 | Tax withholdingCommon Stock | 1,773 | $47.94 | $84,997.62 |
DisclosureSEC source: 0000950170-24-039668 · ownership.xml · nonDerivative · entry 2 Iskra Michael S. · CIK 0001839432 · Interim CEO, EVP & CCO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,350 F3 · shares: Disposition of shares, as set forth above, was in connection with the Issuer's withholding of common shares to satisfy tax withholding obligations related to the issuance of common shares upon release of restricted stock units. Read SEC document |
| March 28, 2024 Filed Apr 1, 2024 20:00 UTC | QuidelOrtho Corp QDEL · Entity 4986 | GrantCommon Stock | 4,925 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-039668 · ownership.xml · nonDerivative · entry 1 Iskra Michael S. · CIK 0001839432 · Interim CEO, EVP & CCO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,123 F1 · shares: Reflects release of restricted stock units that were previously reported on a Form 4. F2 · balance_after: The amount of shares beneficially owned following this transaction includes an additional 291 shares due to the Reporting Person's purchase of shares pursuant to the Issuer's Employee Stock Purchase Plan. Read SEC document |
| February 27, 2024 Filed Feb 29, 2024 17:08 UTC | QuidelOrtho Corp QDEL · Entity 4986 | GrantRestricted Stock Units · Derivative | 21,367 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-023253 · ownership.xml · derivative · entry 1 Iskra Michael S. · CIK 0001839432 · Interim CEO, EVP & CCO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,367 Underlying: Common Stock · 21,367 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F2 · derivative.exercise_date: 21,367 shares will fully vest on June 30, 2025. F2 · derivative.expiration_date: 21,367 shares will fully vest on June 30, 2025. Read SEC document |
| February 08, 2024 Filed Feb 12, 2024 21:45 UTC | QuidelOrtho Corp QDEL · Entity 4986 | GrantRestricted Stock Units · Derivative | 17,905 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-014151 · ownership.xml · derivative · entry 1 Iskra Michael S. · CIK 0001839432 · EVP & CCO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,905 Underlying: Common Stock · 17,905 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F2 · derivative.exercise_date: 11,936 shares will vest in equal installments on February 8, 2025 and February 8, 2026; the remaining 5,969 shares will vest on February 8, 2027. F2 · derivative.expiration_date: 11,936 shares will vest in equal installments on February 8, 2025 and February 8, 2026; the remaining 5,969 shares will vest on February 8, 2027. Read SEC document |
| June 01, 2023 Filed Jun 5, 2023 18:14 UTC | QuidelOrtho Corp QDEL · Entity 4986 | Exercise / conversionRestricted Stock Units · Derivative | 3,594 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-034579 · doc4.xml · derivative · entry 3 Iskra Michael S. · CIK 0001839432 · EVP & CCO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,188 Underlying: Common Stock · 3,594 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F4 · derivative.exercise_date: 3,594 shares vested on June 1, 2023; the remaining 7,188 shares will vest in equal installments on June 1, 2024 and June 1, 2025. F4 · derivative.expiration_date: 3,594 shares vested on June 1, 2023; the remaining 7,188 shares will vest in equal installments on June 1, 2024 and June 1, 2025. Read SEC document |
| June 01, 2023 Filed Jun 5, 2023 18:14 UTC | QuidelOrtho Corp QDEL · Entity 4986 | Tax withholdingCommon Stock | 1,839 | $85.65 | $157,510.35 |
DisclosureSEC source: 0001209191-23-034579 · doc4.xml · nonDerivative · entry 2 Iskra Michael S. · CIK 0001839432 · EVP & CCO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,907 F2 · shares: Disposition of shares, as set forth above, was in connection with the Issuer's withholding of common shares to satisfy tax withholding obligations related to the issuance of common shares upon release of restricted stock units. Read SEC document |
| June 01, 2023 Filed Jun 5, 2023 18:14 UTC | QuidelOrtho Corp QDEL · Entity 4986 | GrantCommon Stock | 3,594 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-034579 · doc4.xml · nonDerivative · entry 1 Iskra Michael S. · CIK 0001839432 · EVP & CCO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,746 F1 · shares: Reflects release of restricted stock units that were previously reported on a Form 4. Read SEC document |
| April 01, 2023 Filed Apr 4, 2023 16:17 UTC | QuidelOrtho Corp QDEL · Entity 4986 | Exercise / conversionRestricted Stock Units · Derivative | 15,825 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-022686 · doc4.xml · derivative · entry 3 Iskra Michael S. · CIK 0001839432 · EVP & CCO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,825 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F5 · derivative.exercise_date: 15,825 shares vested on April 1, 2023. F5 · derivative.expiration_date: 15,825 shares vested on April 1, 2023. Read SEC document |
| April 01, 2023 Filed Apr 4, 2023 16:17 UTC | QuidelOrtho Corp QDEL · Entity 4986 | Tax withholdingCommon Stock | 6,930 | $89.09 | $617,393.70 |
DisclosureSEC source: 0001209191-23-022686 · doc4.xml · nonDerivative · entry 2 Iskra Michael S. · CIK 0001839432 · EVP & CCO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,152 F3 · shares: Disposition of shares, as set forth above, was in connection with the Issuer's withholding of common shares to satisfy tax withholding obligations related to the issuance of common shares upon release of restricted stock units. Read SEC document |
| April 01, 2023 Filed Apr 4, 2023 16:17 UTC | QuidelOrtho Corp QDEL · Entity 4986 | GrantCommon Stock | 15,825 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-022686 · doc4.xml · nonDerivative · entry 1 Iskra Michael S. · CIK 0001839432 · EVP & CCO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,082 F1 · shares: Reflects release of restricted stock units that were previously reported on a Form 4. F2 · balance_after: The amount of shares beneficially owned following this transaction include an additional 257 shares due to the Reporting Person's purchase of shares pursuant to the Issuer's Employee Stock Purchase Plan. Read SEC document |
| March 28, 2023 Filed Mar 30, 2023 19:13 UTC | QuidelOrtho Corp QDEL · Entity 4986 | GrantRestricted Stock Units · Derivative | 14,775 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-021713 · doc4.xml · derivative · entry 2 Iskra Michael S. · CIK 0001839432 · EVP & CCO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,775 Underlying: Common Stock · 14,775 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho Corporation common stock. F1 · derivative.exercise_date: 4,925 shares will vest on the first anniversary date of the grant date, March 28, 2024; 4,925 shares will vest on the second anniversary date of the grant date, March 28, 2025; and 4,925 shares will vest on the third anniversary date of the grant date, March 28, 2026. F1 · derivative.expiration_date: 4,925 shares will vest on the first anniversary date of the grant date, March 28, 2024; 4,925 shares will vest on the second anniversary date of the grant date, March 28, 2025; and 4,925 shares will vest on the third anniversary date of the grant date, March 28, 2026. Read SEC document |
| March 28, 2023 Filed Mar 30, 2023 19:13 UTC | QuidelOrtho Corp QDEL · Entity 4986 | GrantNon-Qualified Stock Option · Derivative | 14,775 | $0.00 Strike: $87.46 | $0.00 |
DisclosureSEC source: 0001209191-23-021713 · doc4.xml · derivative · entry 1 Iskra Michael S. · CIK 0001839432 · EVP & CCO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,775 Underlying: Common Stock · 14,775 shares Expires 2033-03-28 F1 · derivative.exercise_date: 4,925 shares will vest on the first anniversary date of the grant date, March 28, 2024; 4,925 shares will vest on the second anniversary date of the grant date, March 28, 2025; and 4,925 shares will vest on the third anniversary date of the grant date, March 28, 2026. Read SEC document |
| June 01, 2022 Filed Jun 3, 2022 17:14 UTC | QuidelOrtho Corp QDEL · Entity 4986 | GrantRestricted Stock Units · Derivative | 10,782 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-034206 · doc4.xml · derivative · entry 2 Iskra Michael S. · CIK 0001839432 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,782 Underlying: Common Stock · 10,782 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho common stock. F1 · derivative.exercise_date: One-third of the shares will vest annually over a three-year period, commencing on the first anniversary date of the grant. F1 · derivative.expiration_date: One-third of the shares will vest annually over a three-year period, commencing on the first anniversary date of the grant. Read SEC document |
| June 01, 2022 Filed Jun 3, 2022 17:14 UTC | QuidelOrtho Corp QDEL · Entity 4986 | GrantNon-Qualified Stock Option · Derivative | 20,823 | $0.00 Strike: $92.74 | $0.00 |
DisclosureSEC source: 0001209191-22-034206 · doc4.xml · derivative · entry 1 Iskra Michael S. · CIK 0001839432 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,823 Underlying: Common Stock · 20,823 shares Expires 2032-06-01 F1 · derivative.exercise_date: One-third of the shares will vest annually over a three-year period, commencing on the first anniversary date of the grant. Read SEC document |
| May 27, 2022 Filed Jun 1, 2022 16:16 UTC | Ortho Clinical Diagnostics Holdings plc OCDX · Entity 126680 | Disposition to issuerStock Option · Derivative | 79,670 | Not disclosed Strike: $12.56 | Not disclosed |
DisclosureSEC source: 0000899243-22-020385 · doc4.xml · derivative · entry 4 Iskra Michael S. · CIK 0001839432 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares, $0.00001 par value · 79,670 shares Expires 2030-07-27 F3 · price: At the Effective Time, each stock option, whether vested or unvested, was converted into (a) a Coronado Topco stock option on the same terms and conditions as were applicable to such stock option immediately prior to the Effective Time, except as adjusted by the BCA, (b) with respect to the portion of such stock option that is vested as of the Effective Time, the right to receive payment, in cash, equal to the cash consideration payable in respect of the Issuer's securities subject to the vested portion of such stock option and (c) with respect to the portion of such stock option that is not vested as of the Effective Time, the right to receive payment, in cash, equal to the cash consideration payable in respect of the Issuer's securities subject to the unvested portion of such stock option when it vests in accordance with its terms. F3 · derivative.exercise_date: At the Effective Time, each stock option, whether vested or unvested, was converted into (a) a Coronado Topco stock option on the same terms and conditions as were applicable to such stock option immediately prior to the Effective Time, except as adjusted by the BCA, (b) with respect to the portion of such stock option that is vested as of the Effective Time, the right to receive payment, in cash, equal to the cash consideration payable in respect of the Issuer's securities subject to the vested portion of such stock option and (c) with respect to the portion of such stock option that is not vested as of the Effective Time, the right to receive payment, in cash, equal to the cash consideration payable in respect of the Issuer's securities subject to the unvested portion of such stock option when it vests in accordance with its terms. Read SEC document |
| May 27, 2022 Filed Jun 1, 2022 16:16 UTC | Ortho Clinical Diagnostics Holdings plc OCDX · Entity 126680 | Disposition to issuerStock Option · Derivative | 239,010 | Not disclosed Strike: $12.56 | Not disclosed |
DisclosureSEC source: 0000899243-22-020385 · doc4.xml · derivative · entry 3 Iskra Michael S. · CIK 0001839432 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares, $0.00001 par value · 239,010 shares Expires 2029-12-20 F3 · price: At the Effective Time, each stock option, whether vested or unvested, was converted into (a) a Coronado Topco stock option on the same terms and conditions as were applicable to such stock option immediately prior to the Effective Time, except as adjusted by the BCA, (b) with respect to the portion of such stock option that is vested as of the Effective Time, the right to receive payment, in cash, equal to the cash consideration payable in respect of the Issuer's securities subject to the vested portion of such stock option and (c) with respect to the portion of such stock option that is not vested as of the Effective Time, the right to receive payment, in cash, equal to the cash consideration payable in respect of the Issuer's securities subject to the unvested portion of such stock option when it vests in accordance with its terms. F3 · derivative.exercise_date: At the Effective Time, each stock option, whether vested or unvested, was converted into (a) a Coronado Topco stock option on the same terms and conditions as were applicable to such stock option immediately prior to the Effective Time, except as adjusted by the BCA, (b) with respect to the portion of such stock option that is vested as of the Effective Time, the right to receive payment, in cash, equal to the cash consideration payable in respect of the Issuer's securities subject to the vested portion of such stock option and (c) with respect to the portion of such stock option that is not vested as of the Effective Time, the right to receive payment, in cash, equal to the cash consideration payable in respect of the Issuer's securities subject to the unvested portion of such stock option when it vests in accordance with its terms. Read SEC document |
| May 27, 2022 Filed Jun 1, 2022 16:16 UTC | Ortho Clinical Diagnostics Holdings plc OCDX · Entity 126680 | Disposition to issuerStock Option · Derivative | 208,735 | Not disclosed Strike: $6.28 | Not disclosed |
DisclosureSEC source: 0000899243-22-020385 · doc4.xml · derivative · entry 2 Iskra Michael S. · CIK 0001839432 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Ordinary Shares, $0.00001 par value · 208,735 shares Expires 2025-12-21 F3 · price: At the Effective Time, each stock option, whether vested or unvested, was converted into (a) a Coronado Topco stock option on the same terms and conditions as were applicable to such stock option immediately prior to the Effective Time, except as adjusted by the BCA, (b) with respect to the portion of such stock option that is vested as of the Effective Time, the right to receive payment, in cash, equal to the cash consideration payable in respect of the Issuer's securities subject to the vested portion of such stock option and (c) with respect to the portion of such stock option that is not vested as of the Effective Time, the right to receive payment, in cash, equal to the cash consideration payable in respect of the Issuer's securities subject to the unvested portion of such stock option when it vests in accordance with its terms. F3 · derivative.exercise_date: At the Effective Time, each stock option, whether vested or unvested, was converted into (a) a Coronado Topco stock option on the same terms and conditions as were applicable to such stock option immediately prior to the Effective Time, except as adjusted by the BCA, (b) with respect to the portion of such stock option that is vested as of the Effective Time, the right to receive payment, in cash, equal to the cash consideration payable in respect of the Issuer's securities subject to the vested portion of such stock option and (c) with respect to the portion of such stock option that is not vested as of the Effective Time, the right to receive payment, in cash, equal to the cash consideration payable in respect of the Issuer's securities subject to the unvested portion of such stock option when it vests in accordance with its terms. Read SEC document |
| May 27, 2022 Filed Jun 1, 2022 16:16 UTC | Ortho Clinical Diagnostics Holdings plc OCDX · Entity 126680 | Disposition to issuerOrdinary Shares, $0.00001 par value | 150,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-020385 · doc4.xml · nonDerivative · entry 1 Iskra Michael S. · CIK 0001839432 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: Reflects restricted stock units. F2 · price: Pursuant to the Business Combination Agreement, dated December 22, 2021 (the "BCA"), by and among Coronado Topco, Inc. ("Coronado Topco"), Laguna Merger Sub, Inc., Orca Holdco, Inc., Orca Holdco 2, Inc., Quidel Corporation and the Issuer, the Issuer became a wholly owned subsidiary of Coronado Topco upon consummation of the business combinations (the "Effective Time"). At the Effective Time: (a) each of the Issuer's ordinary shares was automatically converted into the right to receive (i) 0.1055 shares of common stock of Coronado Topco and (ii) $7.14 in cash; and (b) each restricted stock unit, whether vested or unvested, was converted into a Coronado Topco equity right of the same type and on the same terms and conditions as were applicable to the corresponding restricted stock unit immediately prior to the Effective Time, which right shall be settled in cash upon vesting. Read SEC document |
| May 27, 2022 Filed Jun 1, 2022 17:34 UTC | QuidelOrtho Corp QDEL · Entity 4986 | GrantRestricted Stock Units · Derivative | 15,825 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-020487 · doc4.xml · derivative · entry 3 Iskra Michael S. · CIK 0001839432 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,825 Underlying: Common Stock · 15,825 shares Expires not disclosed F4 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of QuidelOrtho common stock. F5 · kind: Pursuant to the Business Combination Agreement, each Ortho restricted stock unit was converted into a restricted stock unit representing the right to receive shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions), except as adjusted by the Business Combination Agreement. F6 · derivative.exercise_date: 15,825 shares will vest on April 1, 2023. F6 · derivative.expiration_date: 15,825 shares will vest on April 1, 2023. Read SEC document |
| May 27, 2022 Filed Jun 1, 2022 17:34 UTC | QuidelOrtho Corp QDEL · Entity 4986 | GrantStock Options · Derivative | 16,809 | $0.00 Strike: $119.06 | $0.00 |
DisclosureSEC source: 0000899243-22-020487 · doc4.xml · derivative · entry 2 Iskra Michael S. · CIK 0001839432 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,809 Underlying: Common Stock · 16,809 shares Expires 2024-05-27 F1 · kind: Pursuant to the Business Combination Agreement, dated as of December 22, 2021 (the "Business Combination Agreement") by and among Quidel Corporation, Ortho Clinical Diagnostics Holdings plc ("Ortho"), QuidelOrtho Corporation ("QuidelOrtho"), Orca Holdco, Inc., Laguna Merger Sub, Inc. and Orca Holdco 2, Inc., each Ortho stock option was converted into a Stock Option to purchase shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions), except as adjusted by the Business Combination Agreement. F3 · derivative.exercise_date: 9,804 shares are vested in full; 7,005 shares will vest on July 1, 2022. Read SEC document |
| May 27, 2022 Filed Jun 1, 2022 17:34 UTC | QuidelOrtho Corp QDEL · Entity 4986 | GrantStock Options · Derivative | 22,020 | $0.00 Strike: $59.53 | $0.00 |
DisclosureSEC source: 0000899243-22-020487 · doc4.xml · derivative · entry 1 Iskra Michael S. · CIK 0001839432 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,020 Underlying: Common Stock · 22,020 shares Expires 2025-12-21 F1 · kind: Pursuant to the Business Combination Agreement, dated as of December 22, 2021 (the "Business Combination Agreement") by and among Quidel Corporation, Ortho Clinical Diagnostics Holdings plc ("Ortho"), QuidelOrtho Corporation ("QuidelOrtho"), Orca Holdco, Inc., Laguna Merger Sub, Inc. and Orca Holdco 2, Inc., each Ortho stock option was converted into a Stock Option to purchase shares of common stock of QuidelOrtho on the same terms and conditions (including applicable vesting conditions), except as adjusted by the Business Combination Agreement. F2 · derivative.exercise_date: Vested in full. Read SEC document |
| May 21, 2021 Filed May 25, 2021 16:15 UTC | Ortho Clinical Diagnostics Holdings plc OCDX · Entity 126680 | GrantOrdinary Shares | 150,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-035698 · doc4.xml · nonDerivative · entry 1 Iskra Michael S. · CIK 0001839432 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 F1 · shares: Represents restricted stock units which vest on April 1, 2023. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.